Journals
Consult the user guide
For assistance, please contact us
Consult the user guide
For assistance, please contact us
Add search criteria
Results: 1 - 7 of 7
2021-05-10 [p.917]
Pursuant to Standing Order 39(7), Mr. Lamoureux (Parliamentary Secretary to the President of the Queen’s Privy Council for Canada and Minister of Intergovernmental Affairs and to the Leader of the Government in the House of Commons) presented the returns to the following questions made into orders for return:
Q-575 — Ms. Rood (Lambton—Kent—Middlesex) — With regard to providing the COVID-19 vaccine to Canadian Armed Forces (CAF) members serving abroad: (a) what specific measures are in place to ensure that CAF members serving abroad receive the vaccine; and (b) what is the timeline for when the (i) first dose, (ii) second dose (if applicable), of the vaccine has been or will be administered, broken down by the name of vaccine manufacturer (Pfizer, Moderna, etc.) and the country where CAF members are serving in? — Sessional Paper No. 8555-432-575.
2021-05-10 [p.918]
Q-577 — Ms. Rood (Lambton—Kent—Middlesex) — With regard to the national vaccine management information technology platform (NVMIP): (a) what are the functionalities of the NVMIP; (b) which provinces and territories are currently using the NVMIP; and (c) what are the details the government has related to the usage of NVMIP by the provinces and territories, including (i) the date each province or territory began to use the NVMIP, (ii) which functionalities of NVMIP are each province or territory is using, (iii) the date each province or territory began using each of NVMIP's functionalities? — Sessional Paper No. 8555-432-577.
2021-05-10 [p.919]
Q-582 — Mr. Saroya (Markham—Unionville) — With regard to the government's decision to extend the interval between certain COVID-19 vaccines by up to 105 days: (a) what assessment has the government made on the impact of this decision of those who are suffering from cancer; and (b) what is the government's response to concerns raised by a study from King's College London and the Francis Crick Institute, which found that delays in administering the second dose of more than 21 days leave cancer patients vulnerable to COVID-19? — Sessional Paper No. 8555-432-582.
2021-04-26 [p.827]
Q-513 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the National Advisory Committee on Immunization (NACI) and Health Canada respectively: (a) what scientific evidence, expert opinions, and other factors went into the decision to extend the dosing schedule up to four months between doses of the COVID-19 vaccines; and (b) what is the summary of the minutes of each meeting the NACI had in which dosing timelines were discussed? — Sessional Paper No. 8555-432-513.
2021-01-25 [p.446]
Q-292 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the Prime Minister's announcement in May 2020 of an agreement with CanSino Biologics Inc. (CanSinoBIO) in relation to the development of a potential COVID-19 vaccine: (a) what were the original details of the agreement, as understood by the government in May 2020; (b) on what date did the government first become aware that the agreement would not proceed as planned; (c) on what date did the government become aware that shipments of Ad5-nCoV were being blocked by the Chinese government; (d) what reason, if any, did the Chinese government provide to the government for blocking the shipment; (e) has the government transferred any money or any type of expenditures to CanSinoBIO since January 1, 2020, and, if so, what is the total amount sent, broken down by date of transfer; (f) what are the details of any contracts signed with CanSinoBIO since January 1, 2020, including the (i) amount, (ii) original value, (iii) final value, (iv) date the contract was signed, (v) description of goods or services, including volume; (g) was the National Security and Intelligence Advisor to the Prime Minister advised of the terms agreement prior to the Prime Minister's announcement, and, if so, did he approve of the agreement; (h) was the Department of National Defence or the Canadian Security Intelligence Service informed of the details of the agreement prior to the Prime Minister's announcement, and, if so, did they raise any concerns with the Office of the Prime Minister or the Privy Council Office; and (i) what were the results of any security analysis conducted in relation to CanSinoBIO? — Sessional Paper No. 8555-432-292.
2021-01-25 [p.453]
Q-321 — Mr. Dowdall (Simcoe—Grey) — With regard to the government's decision not to use PnuVax for domestic vaccine production: (a) why did the government decide not to invest in the PnuVax facility so that it could produce vaccines; (b) did the government have any communication with PnuVax about the possibility of vaccine production since March 13, 2020, and, if so, what are the details of each communication; (c) did the government discuss the possibility of a Strategic Innovation Fund investment with PnuVax, and, if not, why not; and (d) has the government received any applications for funding or financial assistance from PnuVax since March 13, 2020, and, if so, what are the details, including the (i) date of application, (ii) government program, (iii) amount applied for, (iv) reason the application was denied, if applicable? — Sessional Paper No. 8555-432-321.
2020-11-20 [p.295]
Pursuant to Standing Order 39(7), Mr. Lamoureux (Parliamentary Secretary to the President of the Queen’s Privy Council for Canada and to the Leader of the Government in the House of Commons) presented the returns to the following questions made into orders for return:
Q-116 — Mr. Tochor (Saskatoon—University) — With regard to the government’s approach to influenza immunization, also known as the flu shot or flu vaccine: (a) how many doses of the flu shot has the government procured or arranged for the 2020-21 flu season; (b) when are all the doses expected to be available and what is the expected timeline regarding how many doses will be available each month; (c) what are the details of any related procurement agreements or arrangements, including (i) date the agreement was signed, (ii) vendor, (iii) amount of doses, (iv) delivery date, (v) financial terms; (d) how many flu shot doses does the government project will be needed for the 2020-21 flu season; and (e) how many flu shot doses does the government project will be available for Canadians by (i) November 30, 2020, (ii) December 31, 2020? — Sessional Paper No. 8555-432-116.
Results: 1 - 7 of 7

Export As: XML CSV RSS

For more data options, please see Open Data